[AI Pharmaceutical Company Iambic, Backed by NVIDIA, Raises $150 Million in U.S. IPO] According to Bloomberg, AI pharmaceutical company Iambic Therapeutics, partially owned by NVIDIA, issued approximately 9.38 million shares at $16 per share, raising $150 million in its U.S. IPO. The pricing falls in the middle of the $15 to $17 range, corresponding to a market valuation of approximately $758 million. The company is expected to begin trading on Nasdaq on October 15 under the ticker IAM. The funds raised will be used to advance three early-stage cancer drug candidates. ARK and the family office of Stanley Druckenmiller have reportedly expressed interest in collectively subscribing for up to $60 million.